pentoxifylline has been researched along with Cardiomyopathies in 8 studies
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with pentoxifylline (P = 0." | 2.70 | The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. ( Bergemann, A; Candy, G; Hopley, M; Sareli, P; Skudicky, D; Sliwa, K, 2002) |
| "Pentoxifylline was well tolerated." | 1.28 | Therapy of ischemic cardiomyopathy with pentoxifylline. ( Barnett, JC; Touchon, RC, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desplantie, O | 1 |
| Tremblay-Gravel, M | 1 |
| Avram, R | 1 |
| Marquis-Gravel, G | 1 |
| Ducharme, A | 1 |
| Jolicoeur, EM | 1 |
| Cardona-Guarache, R | 1 |
| Kron, J | 1 |
| Zang, Z | 1 |
| Li, S | 1 |
| Lin, Y | 1 |
| Li, X | 1 |
| Li, Y | 1 |
| Qin, Y | 1 |
| Wang, H | 1 |
| Jiang, M | 1 |
| Zhu, L | 1 |
| Drímal, J | 1 |
| Zúrová-Nedelcevová, J | 1 |
| Knezl, V | 1 |
| Sotníková, R | 1 |
| Navarová, J | 1 |
| Heidrich, H | 1 |
| Gunther, R | 1 |
| Chelstrom, LM | 1 |
| Wendorf, HR | 1 |
| Schneider, EA | 1 |
| Covalciuc, K | 1 |
| Johnson, B | 1 |
| Clementson, D | 1 |
| Irvin, JD | 1 |
| Myers, DE | 1 |
| Uckun, FM | 1 |
| Sliwa, K | 1 |
| Skudicky, D | 1 |
| Candy, G | 1 |
| Bergemann, A | 1 |
| Hopley, M | 1 |
| Sareli, P | 1 |
| Barnett, JC | 1 |
| Touchon, RC | 1 |
2 reviews available for pentoxifylline and Cardiomyopathies
| Article | Year |
|---|---|
The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies.
Topics: Bromocriptine; Cardiomyopathies; Echocardiography; Female; Humans; Hydrazones; Pentoxifylline; Pregn | 2015 |
[Peripheral arterial occlusions. Principles, possibilities and limits of conservative therapy].
Topics: Ancrod; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cardiomyopathies; Dextrans; Digitalis | 1981 |
1 trial available for pentoxifylline and Cardiomyopathies
| Article | Year |
|---|---|
The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy.
Topics: Adult; Cardiomyopathies; Cardiotonic Agents; Enzyme Inhibitors; Female; Humans; Pentoxifylline; Preg | 2002 |
5 other studies available for pentoxifylline and Cardiomyopathies
| Article | Year |
|---|---|
Treatment of Peripartum Cardiomyopathy: A Call to Action.
Topics: Bromocriptine; Cardiomyopathies; Female; Humans; Hydrazones; Pentoxifylline; Pregnancy; Pregnancy Co | 2015 |
Pentoxifylline Prevents Driamycin-Induced Myocardial Fibrosis and Apoptosis in Rats.
Topics: Animals; Antineoplastic Agents; Cardiomyopathies; Cardiotonic Agents; Caspase 3; Disease Models, Ani | 2015 |
Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2006 |
Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antigens, CD19; Antineoplastic Agents, Ph | 1996 |
Therapy of ischemic cardiomyopathy with pentoxifylline.
Topics: Blood Pressure; Cardiomyopathies; Coronary Disease; Exercise Test; Heart Rate; Humans; Pentoxifyllin | 1990 |